Genetic heterogeneity is widespread in tumors, but poorly documented in cell lines.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma (NHL). Expression array analyses have identified two molecularly distinct forms of the tumor, termed germinal center (GC) and activated B-cell (ABC) forms. 1 Primary mediastinal B-cell lymphoma is a third variant of this tumor marked by its characteristic gene expression signature. 2 Diverse molecular and cytogenetic alterations characterize the three DLBCL subtypes. 3 Translocations affecting BCL2
typically occur in the GC subtype while somatic mutations involving the NFκB pathway are more often found in ABC DLBCL. 3, 4 Cancers evolve under selective forces, including host immunity and drug inhibition, fuelled by mutational alterations explaining the clonal heterogeneity found in tumors including DLBCL. 5, 6 Clonal evolution may also be the reason for the development of molecularly related tumors in one patient. Thus, up to 30% of nodular lymphocyte predominant Hodgkin lymphomas (HL) transform into DLBCL. 7 Furthermore, clonal relationships have been reported for single patients with classical HL and NHL. 8, 9 Cell line U-2932 was derived from a DLBCL patient with a history of HL. 10 According to the results of gene expression analysis, U-2932 meets ABC DLBCL cell line criteria. 11 We recently showed that U-2932 comprises two subclones (R1 and R2)
derived from a presumptive mother clone with genomic BCL2 amplification which acquired distinct sets of secondary rearrangements leading alternatively to the overexpression of BCL6 or MYC in the respective daughter clones. 12 Immunoglobulin gene hypermutation analysis showed that R1 and R2 represent subclones of the original tumor. 12 Thus, the two U-2932 subclones seemed to be ideal to study the cellular consequences of clonal evolution. More than 200 genes showed >10-fold expression differences between R1 and R2. 12 Hence, the two U-2932 subclones sensitively model the cellular consequences of clonal evolution in vitro. Here, we set 4 out to identify molecular causes for subclone-specific gene expression, a necessary first step in addressing the grave therapeutic challenges posed by tumor heterogeneity.
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Chromosome Analysis Suite software version 2.0.1.2 (Affymetrix). Fluorescence in situ hybridization (FISH) was performed using bacterial artificial chromosome (BAC) clones (BACPAC Resources; Oakland, CA, USA) to analyze gene rearrangements at BCL6 using protocols described previously.
15,16
DNA microarray hybridization and quantitative genomic PCR analysis 500 ng total RNA were used for biotin labelling according to the 3´ IVT Express Kit (Affymetrix). 7.5 µg of biotinylated cRNA were fragmented and placed in a hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD, and Cre). Samples were hybridized to an identical lot of Affymetrix GeneChip HG-U133 Plus 2.0 for 16 h at 45°C. Steps for washing and SA-PE staining were processed on the fluidics station 450 using the recommended FS450 protocol (Affymetrix). Image analysis was performed on GCS3000 Scanner and GCOS1.2
Software Suite (Affymetrix). Analysis of data was performed using GeneSpring 11.5.1
(Agilent Technologies; Santa Clara, CA, USA). Signal intensities (raw data) were log2 transformed and normalized using RMA.
Quantitative genomic PCR was performed on a 7500 Applied Biosystems real-time PCR system using the SYBR green assay (Applied Biosystems; Darmstadt, Germany) with ABL1 as internal control and diploid cell line NC-NC as reference.
Primers are shown in Online Supplementary Table 1 .
Western blot analysis
Samples were prepared as described. 17 For separation of cytoplasmic and nuclear
proteins, we applied the nuclear extract kit (Active Motif; La Hulpe, Belgium). Bands on nitrocellulose membranes were visualized with the biotin/streptavidin-horseradish peroxidase system (GE Healthcare; Little Chalfont, UK) in combination with the 7 "Renaissance Western Blot Chemoluminescence Reagent" (Perkin Elmer; Waltham, MA, USA).
Statistical analysis
Data were organized using commonly used spreadsheet programs. Statistical tests were performed using the R software, as described in Online Supplementary Table   2 . 18 For analysis of transcription factor binding sites, we made use of a commercial bioinformatics service (Biobase; Wolfenbüttel, Germany).
RESULTS

Numerical aberrations causing differential gene expression in subclones of the DLBCL cell line U-2932
The DLBCL cell line U-2932 comprises two populations distinguishable by their expression of various B-cell markers including CD20 and CD38. According to the results of immunoglobulin hypermutation and cytogenetic analyses, the populationsnamed R1 and R2 -represent two subclones of the original tumor. 12 Here, we set out to determine why more than 200 genes showed gross (>10-fold) expression differences between R1 and R2 (Online Supplementary Table 3 ).
We applied a whole genome array to investigate the extent to which subclonespecific gene expression might be attributable to numerical aberrations. Twenty-six percent (58/221) of the differentially expressed genes showed concordant numerical disparities between R1 and R2 (Online Supplementary Table 3 ). Statistical analysis of results from copy number aberration and expression data analysis revealed that numerical differences between the two subclones effectively predict differences in gene expression (sensitivity 0.64; specificity 0.94; accuracy 0.78). McNemar´s chisquared test with continuity correction rejected non-correlation of the two parameters with a p-value of 0.0036 compared to 0.05 as level of significance. Actually, for several genes, the correlation between ploidy status and expression level was so stringent that a causal relation could directly be inferred: highly amplified in R1 (13 n) and hemizygously lost in R2 (1 n) were CHMP2B and CGGBP1 on chr 3(p11.1-2) with corresponding differences in gene expression (Fig. 1A /B, Online Supplementary Figure 1) . Loss of expression in population R2 as result of homozygous deletion was found for ITM2B and RB1 on chr 13(q14.2) (Fig. 1A /B, OnlineSupplementary Figure   1 ). Figure 2) . Thus, the major difference between subclones R1 and R2 concerned AhR expression level rather than subcellular localization ( Fig. 2A,   B ).
Therefore, we hypothesized that AhR regulation might underlie differential gene expression in the two U-2932 subclones. To find out how many of the R1 specific genes (126/221 genes with > 10 expression difference were high in R1) were impacted by AhR/ARNT activity, we treated U-2932 R1 cells with the AhR/ARNT inhibitor GNF351 (1 μM, 24 h). GNF351 treatment effected relocalization of AhR from the nucleus to the cytoplasm and led to a downregulation of the AhR/ARNT target CYP1A1 (Fig. 3A, B) . 11/126 R1 high genes (9%) were inhibited by the AhR/ARNT inhibitor, confirming that the difference in AhR levels contributed to non-genomic divergences in gene expression between the two subclones (partially shown in Fig.   3B ).
AhR has been described as epigenetically regulated gene. 22, 23 To test whether AhR expression differences in DLBCL cell lines were subject of epigenetic regulation we treated AhR-positive (SU-DHL6, U-2932 R1) and AhR-negative (OCI-LY19, U-2932 R2) cell lines with inhibitors of histone deacetylation and DNA methylation. Both types of inhibitor significantly induced AhR expression in the negative cell lines, suggesting that differences on the epigenetic level were responsible for the expression of AhR in DLBCL cell lines ( Table 1) . Supportive of this view was the finding that the AhR promoter of the cell line most sensitive to inhibition of DNA methylation (OCI-LY19) was highly methylated (Online supplementary Figure 3 ).
MEF2B: transcriptional regulator of BCL6
One target of the AhR antagonist was MEF2B, member of the `myocyte enhancerbinding factor 2´ family of transcription factors (Fig. 3B ). Confirming that MEF2B lay downstream of AhR/ARNT, ARNT knockdown reduced MEF2B expression in U-2932 R1 cells (Fig. 3C ). MEF2B is a transcriptional regulator that cooperates with corepressors and histone-modifying enzymes. [24] [25] [26] [27] One target of MEF2B is BCL6, a proto-oncogene selectively expressed in GC B-cells. 28 Thus, it was not surprising that AhR/ARNT inhibition not only affected MEF2B but also BCL6 (Fig 3B) . Confirming previously published data, knockdown of MEF2B downregulated BCL6 (Fig. 3D) .
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This together with the U-2932 subclone-restricted expression pattern of AhR, MEF2B
and BCL6 indicated that overexpression of AhR might well explain deregulation of the GC oncogene BCL6 ( Fig. 2A, B ).
To test whether AhR, MEF2B and BCL6 showed coordinated regulation in DLBCL cell lines in general, we analyzed the expression of these genes and of ARNT in a panel of 23 DLBCL cell lines. ARNT was constitutively expressed in all cell lines.
Expression levels of the other three genes varied, but in a highly correlated fashion (Fig. 4, Online Supplementary Figure 4 Until now, it has only been reported that mutant MEF2B enhances transcription of target genes, thereby contributing to the genesis of BCL6 positive DLBCL.
Mutations in MEF2B are frequent in DLBCL and in follicular lymphoma. 4, 24, 29, 30 MEF2B point mutations are carried by 11% of the GC and ABC DLBC lymphomas. 3 However, unmutated MEF2B triggered BCL6 expression in U-2932 cells. 28 Results of sequencing analyses showed that BCL6 levels in cell lines with MEF2B mutations were not generally high (Fig. 4) . We also found that cytogenetic translocations involving BCL6 were uncorrelated with BCL6 expression (Fig. 4) 
BCL6: regulator of gene expression
More than 200 genes were differentially expressed in the two subclones of cell line U- Supplementary Table 3 ). Having shown that copy number aberrations and AhR/ARNT pathway activation were responsible for a substantial proportion of these differences, for most genes the underlying molecular cause for subclonespecific expression remained to be elucidated. To find out the extent to which activation of the transcriptional regulator BCL6 in the R1 clone ( Fig. 2) contributed to this phenomenon, we ectopically expressed this oncogene in the BCL6-negative subclone R2. As previously reported, we infected R2 cells with a retroviral BCL6 construct (MSCV-BCL6-IRES-GFP) or with empty vector (MSCV-IRES-GFP).
(Online
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Treated cells were single-cell sorted to isolate clones with defined levels of BCL6.
According to fluorescence microscopy, all MSCV-BCL6-IRES-GFP clones carried the construct. However, only a minority (5/25) expressed BCL6 mRNA, of which only two expressed BCL6 protein (Online Supplementary Figure 5 ).
Ectopic expression of BCL6 in subclone R2 affected 48 of the 221 (22%) tenfold-ormore differentially expressed genes (Fig. 5A) . Interestingly, 28/48 genes were upregulated by BCL6, although BCL6 is believed to act as transcriptional repressor (Fig. 5A, B) . 35 This also held true at the protein level. Under the influence of BCL6, the B-cell marker CD24 was repressed and, at the same time, CD20, CD22, CD27, CD38 and CD59 were significantly induced (Fig. 5C ). Confirming that BCL6 positively regulates the expression of target genes, the majority of the BCL6 stimulated genes of Figure 5 were positively correlated with BCL6 in a series of B-NHL cell lines (Online Supplementary Table 4) .
Thus, our data demonstrated that differences in BCL6 expression resulted not only in downregulation but also in upregulation of a panel of genes, begging the question how a transcriptional repressor might induce gene expression.
LMO2: mediator for BCL6 initiated gene induction?
To assess whether the BCL6-triggered induction of gene expression was brought about by inhibition of a transcriptional repressor we analyzed which transcription factor binding sites (TFBS) were overrepresented in BCL6-regulated genes. Putative TFBS were analyzed in the promoter region (+/-1000 bp relative to the transcriptional start site) of 160 genes equally up-and downregulated by BCL6 (by at least a factor 2). Confounding our original prediction, BCL6-upregulated genes did not show enrichment for cognate repressors. Conspicuous was that 68% of the BCL6-upregulated genes contained binding sites for LMO2 complexes which were totally absent near downregulated genes.
LMO2 forms complexes with distinct sets of partners in different cell types. In contrast to hematopoetic stem cells and erythroid cells, the LMO2 complex in DLBCL cells excludes TAL1 or GATA proteins. 36 Accordingly, neither TAL1 nor GATA1 nor GATA2 were expressed in the U-2932 subclones (Fig. 6A ). In contrast, other common LMO2 partners, such as E2A (TCF3) and SP1, but also DLBCL-specific partners such as ELK1, LEF1 and NFATc1 were expressed (Fig. 6A) . LMO2 was the only transcription factor complex gene with different expression levels in the two subclones, suggesting that its presence might be crucial for the activity of the whole complex (Fig. 6A ). The expression of LMO2 in U-2932 cells was under the control of BCL6: cells expressing BCL6 were LMO2 positive, cells without BCL6 were LMO2 negative (Fig. 5B, Fig. 6B ). This and the fact that 68% of the BCL6-upregulated genes contained TFBS for LMO2 complexes highlighted LMO2 as a plausible mediator for the inductive effects of BCL6. The observation that BCL6 stimulated expression of LMO2 was noteworthy in another context. On the basis of expression array data, U-2932 had been categorized as ABC DLBCL cell line. 11 However, LMO2
is one of the genes whose expression is indicative for DLBCL of the GC type.
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Applying a short list of five ABC marker genes and five GC markers, the U-2932 subclone R1 differed from R2 by elevated expression of 4/5 GC markers (Fig. 6C ).
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Besides LMO2, also BCL6, MYBL1 and NEK6 are GC markers highly expressed in subclone R1 (Fig. 6C ). Ectopic expression of one of these genes (BCL6) led to an induction of two other GC markers (LMO2 and MYBL1) ( and subclone-specific oncogenes (BCL6 vs MYC).
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Genomic amplification (BCL2; 6-7x in both clones) and a subclone restricted translocation (t(8;14) affecting MYC in R2) explain overexpression of two key oncogenes. Here, we set out to find out why BCL6 was exclusively expressed in subclone R1. BCL6 was not subject to any one of the canonical BCL6 rearrangements in U-2932. The BCL6 repressors STAT5 and IRF4 were unmutated, as was BCL6 exon 1 -important for negative autoregulation of BCL6. Also the transcriptional activator MEF2B, mutated in 11% of DLBCL was unmutated.
However, the wild-type form of MEF2B can also regulate BCL6. 28 MEF2B and BCL6 levels were highly correlated in the U-2932 subclones and in a large panel of DLBCL cell lines. Our inhibitor and knock-down experiments demonstrated that MEF2B is a downstream target of the AhR/ARNT pathway. Consequently AhR and MEF2B levels were highly correlated in a series of DLBCL cell lines. That aberrant activation of signaling cascades can trigger the expression of a characteristic set of target genes is a well-described phenomenon. Inhibitor experiments showed that the AhR/ARNT activation in subclone R1 was responsible for the expression of BCL6 and of ten additional genes. However, gross (>10x), subclone-specific expression differences were observed in 221, not just 11 genes.
Genomic copy number aberrations correlated with and explained subclone specific expression differences for 58 genes. BCL6 itself regulated 48 subclone characterizing genes. Interestingly, 28/48 genes were induced when BCL6 was ectopically expressed, suggesting a novel -most likely indirect -transcriptional role rather than the well-described suppressive role for BCL6. That the GC marker BCL6 triggered expression of other GC markers, MYBL1 and LMO2, is novel. The transcriptional BCL6 target LMO2 forms part of a transcriptional complex with cognate TFBS in 68% of the BCL6 upregulated genes, which are absent in BCL6
repressed genes which suggests that LMO2 plays a role for the observed stimulatory effects of BCL6.
In summary, genomic copy number aberrations, activation of the AhR/ARNT complex, and overexpression of BCL6 conspire to regulate over 100 genes in 14 Nagel S, Ehrentraut S, Tomasch J, Lienenklaus S, Schneider B, Geffers R, et al. 
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SUPPLEMENTAL METHODS
Gene expression analyses
RNA was prepared using the RNeasy Mini kit including the RNase Free DNase Set (Qiagen). TaqMan probes (Applied Biosystems) were used to quantify human AhR Relative expression levels were calculated using the Ct-method. Supplemental Table 2 Statistics 
Preparation of recombinant retroviral supernatants and retroviral transduction
LEGENDS SUPPLEMENTAL FILES
Supplemental Figure 1 -Subclone-specific gene expression. Quantitative RT-PCR was performed to test mRNA levels in the U-2932 subclones R1 and R2. U-2932 R2 was used as reference. Note that structural aberrations on chr 3 and chr 13
correlate with the R1-restricted overexpression of target genes: U-2932 subclone R1
has 32x higher mRNA expression levels of CHMP2B and CGGBP1 than R2, ITM2B
and RB1 is >1000x fold higher expressed in R1 than in R2. was necessary to obtain BCL6 positive subclones.
Supplemental
Supplemental Table 1 -Primers for quantitative genomic PCR. PCR was performed for 40 cycles with 60°C annealing temperature.
Supplemental Table 2 -Statistical evaluation of results. R-programmed statistical analyis.
Supplemental Table 3 -Genes with >10x expression differences between R1 and R2. 
